Consultation Pathway for Progestogen-only Implants

There are several steps to consider when counselling women about the use of progestogen-only implants. Below is a checklist intended for appropriate consultation when considering a progestogen-only implant such as Nexplanon.

Click here to print this page

1. Eligibility for progestogen-only implants

  • Is this the contraceptive of choice?
    Have other options been discussed?
  • Are there any potential risks that may outweigh the benefits?

2. Assessments when considering progestogen-only implants

  • Clinical history assessment: past and present gynaecological, obstetric or medical conditions; prescription, non-prescription or herbal drug use; family history and sexual history
  • Blood pressure/body mass index

3. Provision of information

  • Contraceptive efficacy
  • Time to return of fertility
  • Possible side effects (e.g. bleeding, weight change, mood change, loss of libido, acne and headache)
  • Discontinuation/removal information
  • Drug interactions
  • Potential risk of migration although the implant should always be palpable

4. Timing of insertion

  • Inserting timing/information/wound care
  • Switching from another form of contraception (hormonal and non-hormonal)
  • Postpartum (breastfeeding or non-breastfeeding)
  • Post-termination of pregnancy

5. Information about ongoing use and follow up

  • Reducing the risk of sexually transmitted infections
  • No need for routine follow-up/return if problems
  • Symptoms requiring medical attention

6. Managing problems associated with progestogen-only implants

  • Irregular bleeding
  • Non-palpable implants
  • Pregnancy

7. Removal

  • When, where and how?
  • Potential removal difficulties if inserted too deeply


We would like to gratefully acknowledge the assistance of Diana Mansour (Graingerville Clinic, Newcastle General Hospital) in writing this consultation checklist.
 

 


Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Terms and Conditions
Privacy Policy

Date of Preparation 6/2011
Code 6/12 - NEX.10.GB.9260.AVc

© 2010 Copyright Organon Laboratories Limited. All rights reserved.